Browsing Tag
QUANTI trial
1 post
Gadoquatrane heads to FDA: Can Bayer lead the next generation of low-dose MRI contrast agents?
Bayer targets FDA nod for gadoquatrane, the lowest‑dose macrocyclic MRI contrast agent, potentially reshaping radiology practices globally.